<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786329</url>
  </required_header>
  <id_info>
    <org_study_id>53/14.03.2016</org_study_id>
    <nct_id>NCT02786329</nct_id>
  </id_info>
  <brief_title>Anesthesia and Postoperative Outcome in Colorectal Cancer Patients</brief_title>
  <official_title>The Influence of Anesthesia on Postoperative Outcome and Complications in Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institutul Regional de Gastroenterologie &amp; Hepatologie Prof. dr. Octavian Fodor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Dr. I. Chiricuta Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institutul Regional de Gastroenterologie &amp; Hepatologie Prof. dr. Octavian Fodor</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study aims to compare the influence of TIVA and sevoflurane anesthesia with or without
      lidocaine on postoperative short and long term outcome in patients with colorectal cancer
      undergoing surgery.

      As short term endpoints postoperative pain and opioid consumption, resumption of bowel
      function, PONV, LOS will be registered.

      Long term outcome parameters include: the incidence of chronic pain, 1 and 5 years cancer
      recurrences incidence and mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main goals

        1. Comparative evaluation of the incidence of recurrences after TIVA vs sevoflurane
           anesthesia

        2. Evaluation of the effect of lidocaine infusion associated with TIVA/sevoflurane on the
           incidence of chronic pain and of cancer recurrences and survival.

      Secondary objectives

        1. Evaluation of the influence of lidocaine on postoperative outcome in patients with
           colorectal cancer

        2. Evaluation of the influence of lidocaine on postoperative inflammatory response

        3. Evaluation of the influence of lidocaine on the incidence and severity of postoperative
           pain and outcome in patients with colorectal cancer
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival after TIVA vs sevoflurane anesthesia in patients operated for colorectal cancer</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of recurrences:</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morphine consumption during the first 24 postoperative hours</measure>
    <time_frame>0- 24 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of postoperative pain - verbal response pain (VRPS) score in recovery room and during the first 48 hrs postoperatively</measure>
    <time_frame>0- 48 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resumption of bowel function</measure>
    <time_frame>0-72 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>0-10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative chronic pain</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Colorectal Cancer.</condition>
  <arm_group>
    <arm_group_label>TIVA + lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TIVA-L. Patients allocated to receive TIVA (propofol-fentanyl) with lidocaine infusion.
Interventions: TIVA+lidocaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TIVA+placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TIVA-P. Patients allocated to receive TIVA without lidocaine (placebo). Intervention: TIVA+placebo (saline infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane+placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sevo-P. Patients allocated to receive Sevoflurane anesthesia without lidocaine infusion (placebo).
Intervention: sevoflurane anesthesia +placebo (saline infusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane+lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sevo-L. Patients allocated to receive sevoflurane anesthesia with lidocaine infusion for the first 48 h postoperatively.
Intervention: sevoflurane anesthesia+ lidocaine infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIVA+lidocaine</intervention_name>
    <description>Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively</description>
    <arm_group_label>TIVA + lidocaine</arm_group_label>
    <other_name>TIVA-L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane+lidocaine</intervention_name>
    <description>Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.</description>
    <arm_group_label>Sevoflurane+lidocaine</arm_group_label>
    <other_name>Sevo-L</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TIVA+placebo</intervention_name>
    <description>Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively</description>
    <arm_group_label>TIVA+placebo</arm_group_label>
    <other_name>TIVA-P</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane+placebo</intervention_name>
    <description>Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively</description>
    <arm_group_label>Sevoflurane+placebo</arm_group_label>
    <other_name>Sevo-P</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective surgery

        Exclusion Criteria:

          -  â€¢ persistent chronic pain

               -  chronic medication that may interfere with pain: antiepileptics, NSAID,
                  corticoids

               -  Contraindications for any of the study medications

               -  Significant psychiatric disorders (Axa I) (major depression, bipolar disorders,
                  schizophrenia, etc.)

               -  Significant hepatic (ALAT and/or ASAT &gt; 2 normal values) or renal (plasma
                  creatinine &gt; 2 mg/dl) disorders

               -  Convulsive disorders requiring medication during the last 2 years

               -  Planned regional analgesia/anesthesia (spinal or epidural)

               -  Corticoid dependent asthma

               -  Autoimmune disorders

               -  Anti-arrhythmic medication (verapamil, propafenone, amiodarone) that may
                  interfere with lidocaine's anti-arrhythmic effects

               -  Refusal for study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Ionescu, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela IONESCU, Prof</last_name>
    <phone>+40744771209</phone>
    <email>dionescuati@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caius Breazu, Assist Prof</last_name>
    <phone>+40743010012</phone>
    <email>csbreazu@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica ATI, str Croitorilor nr 19-21</name>
      <address>
        <city>Cluj-napoca</city>
        <state>Cluj</state>
        <zip>400162</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela Ionescu, Prof</last_name>
      <phone>+40744771209</phone>
      <email>dionescuati@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Caius Breazu, Assit Prof</last_name>
      <phone>+40743010012</phone>
      <email>csbreazu@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tiberiu Tat, PhD student</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <reference>
    <citation>Fodale V, D'Arrigo MG, Triolo S, Mondello S, La Torre D. Anesthetic techniques and cancer recurrence after surgery. ScientificWorldJournal. 2014 Feb 6;2014:328513. doi: 10.1155/2014/328513. eCollection 2014. Review.</citation>
    <PMID>24683330</PMID>
  </reference>
  <reference>
    <citation>Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth. 2012 Dec;109 Suppl 1:i17-i28. doi: 10.1093/bja/aes421. Review.</citation>
    <PMID>23242747</PMID>
  </reference>
  <reference>
    <citation>Mao L, Lin S, Lin J. The effects of anesthetics on tumor progression. Int J Physiol Pathophysiol Pharmacol. 2013;5(1):1-10. Epub 2013 Mar 8.</citation>
    <PMID>23525301</PMID>
  </reference>
  <reference>
    <citation>Cakmakkaya OS, Kolodzie K, Apfel CC, Pace NL. Anaesthetic techniques for risk of malignant tumour recurrence. Cochrane Database Syst Rev. 2014 Nov 7;(11):CD008877. doi: 10.1002/14651858.CD008877.pub2. Review.</citation>
    <PMID>25379840</PMID>
  </reference>
  <reference>
    <citation>Cassinello F, Prieto I, del Olmo M, Rivas S, Strichartz GR. Cancer surgery: how may anesthesia influence outcome? J Clin Anesth. 2015 May;27(3):262-72. doi: 10.1016/j.jclinane.2015.02.007. Epub 2015 Mar 11. Review.</citation>
    <PMID>25769963</PMID>
  </reference>
  <reference>
    <citation>Divatia JV, Ambulkar R. Anesthesia and cancer recurrence: What is the evidence? J Anaesthesiol Clin Pharmacol. 2014 Apr;30(2):147-50. doi: 10.4103/0970-9185.129990.</citation>
    <PMID>24803747</PMID>
  </reference>
  <results_reference>
    <citation>Kaba A, Laurent SR, Detroz BJ, Sessler DI, Durieux ME, Lamy ML, Joris JL. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology. 2007 Jan;106(1):11-8; discussion 5-6.</citation>
    <PMID>17197840</PMID>
  </results_reference>
  <results_reference>
    <citation>McCarthy GC, Megalla SA, Habib AS. Impact of intravenous lidocaine infusion on postoperative analgesia and recovery from surgery: a systematic review of randomized controlled trials. Drugs. 2010 Jun 18;70(9):1149-63. doi: 10.2165/10898560-000000000-00000. Review.</citation>
    <PMID>20518581</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2016</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institutul Regional de Gastroenterologie &amp; Hepatologie Prof. dr. Octavian Fodor</investigator_affiliation>
    <investigator_full_name>Prof.Dr.Daniela Ionescu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>TIVA</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>lidocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Regular meeting for sharing data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

